Gennex Laboratories Limited

GENNEX6

INE509C01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 16/07/2024 pm IST			5-day change	1st Jan Change
14.16 ^INR	+0.21%		-8.47%	-15.76%

30/05	Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
14/02	Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Gennex Laboratories Ltd. Appoints A Ranga Rao Pantulu Appointed as Additional Director, with Effect from December 21, 2020

December 21, 2020 at 12:59 pm IST

Gennex Laboratories Ltd. Appointed Dr. Avasarala Ranga Rao Pantulu as additional director designated as Non- executive Director of the Company, pursuant to provisions of Section 149 and 161 of the Companies Act, 2013 with effect from December 21, 2020.

Latest news about Gennex Laboratories Limited

Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	14/02	CI
Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director	01/02	CI
Gennex Laboratories Gets Good Manufacturing Practices Certificate from Indian Regulator	13/12	MT
Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd	02/12	CI
Gennex Laboratories Board to Consider Raising Funds Via Equity	29/11	MT
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Gennex Laboratories Gets Permission to Manufacture, Sell Fexofenadine, Minoxidil	10/23/10	MT
Gennex Laboratories Limited Obtains Approval of Additional Products from Drug Control Administration, Government of Telangana	09/23/09	CI
Gennex Laboratories Gets WHO-GMP Certification from Drug Control Administration, Government of Telangana	11/23/11	MT
Gennex Laboratories Arm Gets Drug Manufacturing License	02/23/02	MT
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	31/23/31	CI
Gennex Laboratories Limited Appoints Dinesh Kumar Kejriwal as Company Secretary & Compliance Officer	20/23/20	CI
Gennex Laboratories Limited completed the acquisition of 6.73% minority stake in Deccan Remedies Limited.	01/23/01	CI
Gennex Laboratories Limited Approves the Acceptance of Resignation of Rajesh Vankadara as Company Secretary & Compliance Officer	14/23/14	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023	07/23/07	CI
Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana	27/22/27	CI
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/22/30	CI
Gennex Laboratories Board OKs Up to $5.3 Million Rights Issue	06/22/06	MT
Gennex Laboratories Board to Consider Fundraising Via Debt or Equity Offering	28/22/28	MT
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI

Chart Gennex Laboratories Limited

Duration

Period

More charts

Company Profile

Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The Company has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company operates through the Pharmaceutical Products (Bulk Drugs) segment. The Company's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant, and Sertraline Hcl, which is a selective serotonin reuptake inhibitors (SSRIS). The Company has manufacturing facilities in India which cater to both domestic and international markets.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENNEX LABORATORIES LIMITED	-15.76%	3.85Cr
ELI LILLY AND COMPANY	+61.53%	85TCr
NOVO NORDISK A/S	+32.92%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ASTRAZENECA PLC	+13.30%	24TCr
NOVARTIS AG	+16.37%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	17TCr